Answers are grounded in this paper and cite their sources.
BACKGROUND: Dermatophytoses are one of the most common skin diseases that have been largely simple to treat. However, in recent years, these infections have become recalcitrant to treatment which can possibly be due to antifungal resistance. AIM: To analyze the resistance pattern of patients with recalcitrant dermatophytoses. MATERIALS AND METHODS: A cross-sectional evaluation was undertaken of 40 consecutive patients with recalcitrant tinea corporis/cruris/both who had taken systemic antifungal treatment and did not respond completely to therapy or had recurrent lesion within 1 month of stopping the therapy. Terbinafine, fluconazole, itraconazole, ketoconazole, amphotericin B, and voriconazole were the antifungals tested using broth microdilution assay for antifungal susceptibility testing of dermatophytes, and MIC50, 90 values were recorded. RESULTS: of 0.0625 and 0.25 μg/ml, respectively. All isolates had reduced susceptibility to fluconazole. CONCLUSION: resistance (>1 μg/ml) to antifungals was not seen and probably may not be a cause of treatment failure. Possibly, treatment failure lies in the intricate host fungal interaction and virulence of species which help it to evade host immune response.
No takes yet. Share an insight, caveat, or question.
Arora et al. (2018) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: